Three weeks after Redx Pharma and Jounce Therapeutics announced a merger, their plans have been disrupted by an unsolicited offer for Jounce from little-known Concentra Bi
UK biotech Redx Pharma and US-based Jounce Therapeutics have agreed to merge, pooling their resources to create a new company dedicated to the development of small-molecul
Gilead Sciences must like what it has seen in a two-year-old partnership with Jounce Therapeutics for a CCR8-targeting cancer immunotherapy – it has just agreed to take full ownership of th
A phase 2 trial of Jounce Therapeutics' ICOS agonist vopratelimab has ended in failure, casting further doubt about the validity of ICOS as a target for cancer therapies.
In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho
